Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor

Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study

(2020) Najat C. Daw et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

(2020) Jennifer Y. Ge et al.   Nature Communications

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer

(2019) Carmelo Nucera   Oncotarget

The Expanding World of N-MYC–Driven Tumors

(2018) David S. Rickman et al.   Cancer Discovery

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group

(2016) Ariadne H.A.G. Ooms et al.   CLINICAL CANCER RESEARCH

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

(2016) G. W. Rhyasen et al.   MOLECULAR CANCER THERAPEUTICS

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma

(2016) Omid Tavana et al.   NATURE MEDICINE

Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1

(2016) Camille Jacques et al.   Oncotarget

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

(2015) A. Henssen et al.   CLINICAL CANCER RESEARCH

Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration

(2015) Jeffrey S. Dome et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma

(2015) Daniel R. Carter et al.   Science Translational Medicine

Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma

(2015) Sora Lee et al.   SURGERY

Multiple mechanisms of MYCN dysregulation in Wilms tumour

(2015) Richard D. Williams et al.   Oncotarget

BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells

(2015) Emma K Baker et al.   Scientific Reports

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

(2015) Anton George Henssen et al.   Oncotarget

Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma

(2015) Sujatha Venataraman et al.   Oncotarget

c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells

(2014) J. E. Roderick et al.   BLOOD

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle

(2014) François Lamoureux et al.   Nature Communications

BET Bromodomain Inhibition Triggers Apoptosis of NF1-Associated Malignant Peripheral Nerve Sheath Tumors through Bim Induction

(2014) Amish J. Patel et al.   Cell Reports

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

(2013) Bjoern Chapuy et al.   CANCER CELL

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study

(2013) Gemma Gatta et al.   LANCET ONCOLOGY

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

(2013) Anastasia Wyce et al.   PLoS One

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Neuroblastoma and MYCN

(2013) M. Huang et al.   Cold Spring Harbor Perspectives in Medicine

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study

(2011) Amanda M. Termuhlen et al.   PEDIATRIC BLOOD & CANCER

Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and theMYCandMYCNLoci

(2009) Stefan Pfister et al.   JOURNAL OF CLINICAL ONCOLOGY